Preclinical efficacy of carfilzomib in BRAF‐mutant colorectal cancer models

Preclinical efficacy of carfilzomib in BRAF‐mutant colorectal cancer models

Serine/threonine‐protein kinase B‐raf (BRAF) mutations are found in 8–15% of colorectal cancer patients and identify a subset of tumors with poor outcome in the metastatic setting. We have previously reported that BRAF‐mutant human cells display a high rate of protein production, causing proteotoxic...

Full description

Bibliographic Details
Main Authors: Federica Maione, Daniele Oddo, Federica Galvagno, Chiara Falcomatà, Marta Pandini, Marco Macagno, Valeria Pessei, Ludovic Barault, Chiara Gigliotti, Alessia Mira, Giorgio Corti, Simona Lamba, Chiara Riganti, Barbara Castella, Massimo Massaia, Roland Rad, Dieter Saur, Alberto Bardelli, Federica Di Nicolantonio
Format: Article
Language:English
Published: Wiley 2024-06-01
Series:Molecular Oncology
Subjects:
BRAF mutant colorectal cancer
endoplasmic reticulum stress
immune microenvironment
immunogenic cell death
oncogene
proteasome inhibitors
Online Access:https://doi.org/10.1002/1878-0261.13595

Internet

https://doi.org/10.1002/1878-0261.13595

Similar Items